文献速递骨软组织肉瘤与黑色素瘤

免疫治疗在八十岁及以上转移性黑色素瘤患者中趋于成熟

Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
PubMed 文献 · Eur J Cancer · 2019-01-14

该回顾性队列研究纳入144例≥65岁接受抗PD-1治疗的转移性黑色素瘤患者,比较65-79岁组(82例)与80-100岁组(62例)的疗效与毒性。结果显示80-100岁组完全缓解率显著更高(47.9% vs 20%,p=0.001),总缓解率有升高趋势但未达统计学显著(73.9% vs 62.3%,p=0.09),两组PFS与OS无显著差异,毒性相似。

要点

  • 80-100岁组完全缓解率显著高于65-79岁组(47.9% vs 20%,p=0.001)。
  • 两组总缓解率分别为73.9%与62.3%,差异未达统计学显著(p=0.09)。
  • 两组PFS与OS无显著差异,G2-4不良事件发生率相似(22.8%-25.6%)。

核心结论

  • 老年患者对 anti-PD-1 治疗显示出增强的缓解,且在高龄患者中年龄增长可能预测更好的缓解和相当的生存。

研究设计与样本

  • 回顾性收集2013年至2018年间接受抗PD-1治疗的65-100岁转移性黑色素瘤患者记录,共144例。
  • 65-79岁组(A组)82例,中位年龄71.5岁;80-100岁组(B组)62例,中位年龄84岁(范围80-97岁)。
  • 共124例可评估缓解(A组76例,B组48例)。
  • 采用Cox回归、t检验和卡方检验进行统计分析。

主要发现

  • 基线参数除B组体能状态更差外(p=0.001)具有可比性。
  • 总缓解率A组62.3% vs B组73.9%(p=0.09),差异未达统计学显著。
  • 完全缓解率B组47.9% vs A组20%(p=0.001),B组显著更高。
  • 两组PFS与OS无显著差异。
  • 全部患者G2-4不良事件发生率为22.8%-25.6%,两组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Recent data hint at better response to therapy for patients over age 65 years. Patients with metastatic melanoma in their 80's and 90's pose a clinical challenge. We describe a cohort of 144 patients ≥65 years and analyse the efficacy and toxicity of anti-PD-1 therapy in ages 80-100 years compared with ages 65-79 years. Records of metastatic melanoma patients aged 65-100 years treated with anti-PD-1 were collected retrospectively. Baseline parameters, response rate (overall response rate [ORR]), best response, progression-free survival (PFS) and overall survival (OS) and immune-related adverse events were analysed. Cox regression, t test, and chi-square test were used for statistical analysis. Five hundred patients were treated with anti-PD-1 agents between 2013 and 2018.Eighty-two patients were aged 65-79 years (group A, median 71.5 years), and 62 patients were aged 80-100 years (group B, median 84 years, range 80-97 years). Baseline parameters were comparable except for worse PS in group B (p = 0.001). One hundred twenty-four patients were evaluable for analysis of response (76 group A, 48 group B). A trend was noted for higher ORR in the older group with 62.3% for group A and 73.9% for group B (p = 0.09). Complete response was significantly higher in group B versus group A (47.9% versus 20%, p = 0.001). No significant difference was found in PFS or OS between the groups. Toxicity for all patients was similar at 22.8%-25.6% G2-4 adverse events. Elderly patients show enhanced response to anti-PD-1 therapy. Increasing age within the elderly patients group may predict an even better response to therapy and comparable survival in patients of very old age.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ben-Betzalel G, Steinberg-Silman Y, Stoff R, et al. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. Eur J Cancer. 2019. PMID: 30648631. doi:10.1016/j.ejca.2018.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。